Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ultragenyx Pharmaceutical Inc.

www.ultragenyx.com

Latest From Ultragenyx Pharmaceutical Inc.

Pipeline Watch: Phase III Progress With Abemaciclib, Esketamine

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Dismay With Veliparib, Tarextumab, House Dust Mite Allergens

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Will Ultragenyx/Kyowa Hypophosphatemia Data Support Uptake?

Ultragenyx and partner Kyowa Hakko Kirin said burosumab (KRN23) met the primary endpoint regarding phosphate levels in a Phase III study that enrolled adult X-linked hypophosphatemia patients, but small effects on two out of three secondary endpoints could impact the product's use.

Clinical Trials Rare Diseases

Pipeline Watch: Phase III Readouts For Alectinib and Omadacycline

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ultragenyx Pharmaceutical LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ultragenyx Pharmaceutical Inc.
  • Senior Management
  • Emil Kakkis, MD, PhD, Pres. & CEO
    Shalini Sharp, SVP, CFO
    Jayson Dallas, MD, SVP, Chief Commercial Officer
    Thomas Kassberg, SVP, CBO
    Sunil Agarwal, MD, SVP, CMO
  • Contact Info
  • Ultragenyx Pharmaceutical Inc.
    Phone: (415) 483-8800
    60 Leveroni Ct.
    Novato, CA 94949
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register